Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites

Xenobiotica

Volumn 35, Issue 10-11, 2005, Pages 1055-1066

  Mallants, R ^a   Van Oosterwyck, K ^a   Van Vaeck, L ^a   Mols, R ^a   De Clercq, E ^b   Augustijns, P ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

Hepatobiliary elimination; Intestinal absorption; MRP2; Tenofovir

Indexed keywords

DRUG METABOLITE; ESTER DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN 2; PROBENECID; TENOFOVIR; TENOFOVIR DISOPROXIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILE; CELL STRAIN CACO 2; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DISPOSITION; DRUG ELIMINATION; HEPATOBILIARY SYSTEM; HUMAN; HUMAN CELL; INTESTINE; MALE; NONHUMAN; RAT; STATISTICAL SIGNIFICANCE;

ADENINE; ANIMALS; BILE DUCTS; CACO-2 CELLS; HUMANS; INTESTINES; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; METABOLIC CLEARANCE RATE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHOSPHONIC ACIDS; PROBENECID; RATS; RATS, WISTAR; URICOSURIC AGENTS;

ANIMALIA;

EID: 30344432397     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250500354493     Document Type: Article

References (23)

1. Anonymous, 2004. Tenofovir: New indication. For first-line antiretroviral therapy: Wait and see. Prescrire International 13:180-182.
2. Arimilli MN, Kim CU, Dougherty J, Mulato A, Oliyai R, Shaw JP, Cundy KC, Bischofberger N. 1997. Synthesis, in vitro biological evaluation, and oral bioavailability of 9-[(2-phosphonylmethoxy)propyl]adenine (PMPA) prodrugs. Antiviral Chemistry and Chemotherapy 8:557-564.
3. Cundy KC, Sueoka C, Lynch GR, Griffin L, Lee WA, Shaw JP. 1998. Pharmacokinetics and bioavailability of the anti-human immunodeficiency virus nucleotide analog 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Antimicrobial Agents and Chemotherapy 42:687-690.
4. Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S, Kahn JO. 1998. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl] adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrobial Agents and Chemotherapy 42:2380-2384.
5. Feller N, Broxterman HJ, Wahrer DCR, Pinedo HM. 1995. ATP-dependent efflux of calcein by the multidrug resistance protein (MRP): No inhibition by intracellular glutathione depletion. Federation of European Biochemical Societies Letters 368:385-388.
6. Gallant JE, Deresinski S. 2003. Tenofovir disoproxil fumarate. Clinical Infectious Diseases 37:944-950.
7. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK. 2004. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. Journal of the American Medical Association 292:191-201.
8. Gotoh Y, Suzuki H, Kinoshita S, Hirohashi T, Kato Y, Sugiyama Y. 2000. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance-associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. Journal of Pharmacology and Experimental Therapeutics 292:433-439.
9. Hogg RS, O'Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, Montaner JS. 1997. Decline in deaths from AIDS due to new antiretrovirals. Lancet 349:1294.
10. Hooijberg JH, Broxterman HJ, Kool M, Assaraf YG, Peters GJ, Noordhuis P, Scheper RJ, Borst P, Pinedo HM, Jansen G. 1999. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Research 59:2532-2535.
11. Kearney BP, Flaherty JF, Shah J. 2004. Tenofovir disoproxil fumarate. Clinical Pharmacokinetics 43:595-612.
12. McDonagh AF, Lightner DA, Boiadjiev SE, Brower JO, Norona WS. 2002. Hepatobiliary excretion of dipyrrinone sulfonates in MRP2-deficient [TR(-)] rats. Bioorganic and Medical Chemistry Letters 12:2483-2486.
13. Naesens L, Balzarini J, De Clercq E. 1992. Acyclic adenine nucleoside phosphonates in plasma determined by high-performance liquid chromatography with fluorescence detection. Clinical Chemistry 38:480-485.
14. Naesens L, Bischofberger N, Augustijns P, Annaert P, Van den Mooter G, Arimilli MN, Kim CU, De Clercq E. 1998. Antiretroviral efficacy and pharmacokinetics of oral bis(isopropyloxycarbonyloxymethyl)9-(2- phosphonylmethoxypropyl)adenine in mice. Antimicrobial Agents and Chemotherapy 42:1568-1573.
15. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. 1997. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chemistry and Chemotherapy 8:1-23.
16. Oude Elferink R, Groen AK. 2002. Genetic defects in hepatobiliary transport. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1586:129-145.
17. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD, The HIV Outpatient Study Investigators. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New England Journal of Medicine 338:853-860.
18. Paulusma CC, Bosma PJ, Zaman GJ, Bakker CT, Otter M, Scheffer GL, Scheper RJ, Borst P, Oude Elferink RP. 1996. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science 271:1126-1128.
19. Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, Cundy KC. 1997. Metabolism and pharmacokinetics of novel oral prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in dogs. Pharmaceutical Research 14:1824-1829.
20. Squires K, Pozniak AL, Pierone G, Jr, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF, Cheng A. 2003. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection: A randomized trial. Annals of Internal Medicine 139:313-320.
21. Van Gelder J, Annaert P, Naesens L, De Clercq E, Van den MG, Kinget R, Augustijns P. 1999. Inhibition of intestinal metabolism of the antiviral ester prodrug bis(POC)-PMPA by nature-identical fruit extracts as a strategy to enhance its oral absorption: An in vitro study. Pharmaceutical Research 16:1035-1040.
22. Van Gelder J, Deferme S, Annaert P, Naesens L, De Clercq E, Van den Mooter G, Kinget R, Augustijns P. 2000. Increased absorption of the antiviral ester prodrug tenofovir disoproxil in rat ileum by inhibiting its intestinal metabolism. Drug Metabolism and Disposition 28:1394-1396.
23. Van Gelder J, Deferme S, Naesens L, De Clercq E, Van den Mooter G, Kinget R, Augustijns P. 2002. Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures. Drug Metabolism and Disposition 30:924-930.